TIGIT and neoplasm: Tumor-bearing mice treated with combination therapy showed higher amounts of CD8+ TILs that expressed IFN-γ, Granzyme B, Perforin, TNF-α, TRAIL and FasL than untreated mice, OX or TIGIT mAb alone (Figure 3C).